BRPI0410378A - tratamento de distúrbios psicóticos e depressivos - Google Patents
tratamento de distúrbios psicóticos e depressivosInfo
- Publication number
- BRPI0410378A BRPI0410378A BRPI0410378-5A BRPI0410378A BRPI0410378A BR PI0410378 A BRPI0410378 A BR PI0410378A BR PI0410378 A BRPI0410378 A BR PI0410378A BR PI0410378 A BRPI0410378 A BR PI0410378A
- Authority
- BR
- Brazil
- Prior art keywords
- psychosis
- psychotic
- depression
- compound
- treatment
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 5
- 208000020401 Depressive disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024254 Delusional disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010061285 Mental disorder due to a general medical condition Diseases 0.000 abstract 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 abstract 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000002545 drug psychosis Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 201000003995 melancholia Diseases 0.000 abstract 1
- 208000002851 paranoid schizophrenia Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Abstract
"TRATAMENTO DE DISTúRBIOS PSICóTICOS E DEPRESSIVOS". A presente invenção refere-se a um método para tratamento de condições e perturbações psiquiátricos selecionados dentre distúrbio delirante, psicose associada à demência, tal como psicose associada à doença de Alzheimer, psicose associada a uma síndrome cerebral orgânica (por exemplo, acidente vascular cerebral ou uma infecção viral tal como uma infecção HIV) e psicose induzida por droga em mamíferos, incluindo seres humanos, compreendendo a administração de uma quantidade eficaz de um composto da fórmula I: ou um seu sal de adição de ácido farmaceuticamente aceitável, em que Ar, n, X e Y são conforme definidos. A presente invenção também refere-se a um método para o tratamento de um distúrbio depressivo selecionado dentre depressão melancólica, depressão severa, depressão psicótica e depressão resistente ao tratamento em mamíferos, incluindo seres humanos, compreendendo a administração de um composto da fórmula I, ou um sal de adição de ácido farmaceuticamente aceitável de tal composto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47138003P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001546 WO2004100954A1 (en) | 2003-05-16 | 2004-05-03 | Treatment of psychotic and depressive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0410378A true BRPI0410378A (pt) | 2006-06-13 |
Family
ID=33452443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0410378-5A BRPI0410378A (pt) | 2003-05-16 | 2004-05-03 | tratamento de distúrbios psicóticos e depressivos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050004137A1 (pt) |
| EP (1) | EP1633360A1 (pt) |
| JP (1) | JP2007502856A (pt) |
| BR (1) | BRPI0410378A (pt) |
| CA (1) | CA2525866A1 (pt) |
| CL (1) | CL2004000964A1 (pt) |
| MX (1) | MXPA05012391A (pt) |
| TW (1) | TW200425894A (pt) |
| WO (1) | WO2004100954A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323451T7 (es) | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| AR056968A1 (es) * | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| JP2009524637A (ja) * | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| AU2007307635A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| US20110294842A9 (en) * | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| JP5270943B2 (ja) * | 2008-03-28 | 2013-08-21 | 大阪瓦斯株式会社 | フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法 |
| JP5367824B2 (ja) * | 2008-09-22 | 2013-12-11 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬 |
| JO3032B1 (ar) * | 2008-10-17 | 2016-09-05 | Xenon Pharmaceuticals Inc | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| MA41169A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| DE3923045A1 (de) * | 1989-07-13 | 1991-01-17 | Merck Patent Gmbh | Indolderivate |
| JP3274579B2 (ja) * | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | 脳血管障害に伴う精神症候治療剤 |
| DK0904273T3 (da) * | 1996-05-07 | 2003-07-07 | Pfizer | Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| EP1073432B1 (en) * | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| CA2363942A1 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| CA2324813A1 (en) * | 1999-11-10 | 2001-05-10 | Susan Beth Sobolov-Jaynes | Combination treatment for depression and anxiety |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| AU783516B2 (en) * | 2001-04-30 | 2005-11-03 | Warner-Lambert Company | Methods, kits and compositions for using pyrrole derivatives |
| EP1397145B1 (en) * | 2001-06-19 | 2006-09-06 | Norbert Müller | Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders |
-
2004
- 2004-05-03 EP EP04730896A patent/EP1633360A1/en not_active Withdrawn
- 2004-05-03 CA CA002525866A patent/CA2525866A1/en not_active Abandoned
- 2004-05-03 JP JP2006530648A patent/JP2007502856A/ja active Pending
- 2004-05-03 MX MXPA05012391A patent/MXPA05012391A/es unknown
- 2004-05-03 BR BRPI0410378-5A patent/BRPI0410378A/pt not_active IP Right Cessation
- 2004-05-03 WO PCT/IB2004/001546 patent/WO2004100954A1/en not_active Ceased
- 2004-05-05 CL CL200400964A patent/CL2004000964A1/es unknown
- 2004-05-12 TW TW093113352A patent/TW200425894A/zh unknown
- 2004-05-12 US US10/844,079 patent/US20050004137A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007502856A (ja) | 2007-02-15 |
| MXPA05012391A (es) | 2006-02-02 |
| EP1633360A1 (en) | 2006-03-15 |
| WO2004100954A1 (en) | 2004-11-25 |
| US20050004137A1 (en) | 2005-01-06 |
| TW200425894A (en) | 2004-12-01 |
| CA2525866A1 (en) | 2004-11-25 |
| CL2004000964A1 (es) | 2005-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0410378A (pt) | tratamento de distúrbios psicóticos e depressivos | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
| BR112018000041A2 (pt) | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| BR112012015714A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer | |
| UY28817A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegerativos | |
| NO20052546L (no) | Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon. | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| PT1586319E (pt) | Inibidores de gsk-3 | |
| WO2007070598A3 (en) | Nucleotide and oligonucleotide prodrugs | |
| CL2024000858A1 (es) | Composiciones de agentes de arni de proteína tau asociada a microtúbulos (mapt) | |
| BR112015011213A2 (pt) | Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| BR112022020814A2 (pt) | Métodos para tratamento de síndrome de liberação de citocina | |
| BR112019004243A2 (pt) | composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente | |
| MX2024004552A (es) | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas. | |
| AR068438A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona | |
| BR0211830A (pt) | Dose única de azitromicina | |
| BR112012022209A2 (pt) | composições farmacêuticas compreendendo monoterpenos | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| EP4414037A3 (en) | Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2142 DE 24/01/2012. |